Peak Bio Stock (NASDAQ:PKBO)

Revenue Ownership Financials Chart

Previous Close

$0.05

52W Range

- - $0.27

50D Avg

$0.10

200D Avg

$0.03

Market Cap

$531.87K

Avg Vol (3M)

$2.00K

Beta

1.78

Div Yield

-

PKBO Company Profile

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 15, 2021

Website

PKBO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23
Grant	$2.50M	$2.50M	$2.50M	$2.60M	$2.90M

Fiscal year ends in Dec 23 | Currency in USD

PKBO Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$367.88K	$607.68K	$528.31K
Operating Income	$-13.07M	$-11.85M	$-9.07M
Net Income	$-12.83M	$-13.09M	$-8.29M
EBITDA	$-13.07M	$-11.88M	$-8.89M
Basic EPS	$-0.61	$-0.74	$-0.48
Diluted EPS	$-0.61	$-0.74	$-0.48

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
CSBR	Champions Oncology, Inc.
MNOV	MediciNova, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG